作者
Hsiao‐Wei Tsao,Seth Anderson,Kenneth J. Finn,Jonathan Perera,Lomax F. Pass,Emily M. Schneider,Aiping Jiang,Rachel Fetterman,Cun Lan Chuong,Kaiya Kozuma,Marcia Stickler,Marc Creixell,Susan Klaeger,Kshiti Meera Phulphagar,Suzanna Rachimi,Eva K. Verzani,Niclas Olsson,Juan Dubrot,Matthew F. Pech,Whitney Silkworth,Sarah Kate Lane-Reticker,Peter M. Allen,Karim Yaqub Ibrahim,Nelson H. Knudsen,Anthony Cheng,Adrienne H. Long,Hakimeh Ebrahimi-Nik,Sarah Kim,Peter P. Du,Arvin Iracheta‐Vellve,Emily Robitschek,Juliette S. M. T. Suermondt,Thomas Davis,Clara Wolfe,Trisha Atluri,Kira E. Olander,Jason S. Rush,Thomas B. Sundberg,Fiona E. McAllister,Jennifer G. Abelin,Ari Firestone,David Stokoe,Steven A. Carr,Fiona Harding,Kathleen B. Yates,Robert T. Manguso
摘要
The aminopeptidase, endoplasmic reticulum aminopeptidase 1 (ERAP1), trims peptides for loading into major histocompatibility complex class I (MHC class I), and loss of this activity has broad effects on the MHC class I peptidome. Here, we investigated the impact of targeting ERAP1 in immune checkpoint blockade (ICB), as MHC class I interactions mediate both activating and inhibitory functions in antitumor immunity. Loss of ERAP sensitized mouse tumor models to ICB, and this sensitivity depended on CD8